Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
CinCor Pharma, founded in 2018 and headquartered in Waltham, Massachusetts, is a biopharmaceutical company specializing in developing treatments for hypertension and cardiovascular diseases. The company's primary focus lies in creating therapeutic solutions for conditions such as hypertension, chronic kidney disease, and primary aldosteronism. Since its inception, CinCor Pharma has made significant strides in the pharmaceutical industry, raising a total of $193 million in funding.
In a notable development, AstraZeneca acquired CinCor Pharma in February 2023, valuing the company between $1.3 billion and $1.8 billion. This acquisition marks a significant milestone in CinCor Pharma's journey and underscores the potential value of its research and development efforts in the cardiovascular field.
Given the recent acquisition by AstraZeneca, there is currently no information available regarding CinCor Pharma's IPO prospects. The company's future as a publicly traded entity remains uncertain, and any discussions about potential stock offerings or investment opportunities would be purely speculative at this point.
Investors interested in the biopharmaceutical sector, particularly in companies focusing on cardiovascular treatments, may want to keep an eye on CinCor Pharma's progress within the AstraZeneca portfolio. However, it's important to note that the acquisition likely changes the landscape for potential individual investment opportunities in CinCor Pharma as a standalone entity.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While CinCor Pharma's IPO prospects are still developing, investors interested in the biopharmaceutical sector don't have to wait on the sidelines. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides opportunities to invest in potential industry leaders, including those in the healthcare and biotech sectors, with lower minimum investments than traditional private equity channels. This allows you to potentially benefit from the growth of innovative companies like CinCor Pharma before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
